Wave Life Sciences (WVE) Stock Overview
A clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
WVE Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
ST
Fair Value from
US$21.5363.5% undervalued intrinsic discount
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeWave Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.24 |
| 52 Week High | US$21.73 |
| 52 Week Low | US$5.02 |
| Beta | -1.32 |
| 1 Month Change | 1.97% |
| 3 Month Change | -46.17% |
| 1 Year Change | 10.70% |
| 3 Year Change | 87.08% |
| 5 Year Change | 23.55% |
| Change since IPO | -54.75% |
Recent News & Updates
Seeking Alpha • May 07
Wave Life Sciences: Good Platform, Mixed Clinical Trial Data, Hold
Summary Wave Life Sciences is advancing stereopure oligonucleotide therapeutics, with WVE-006 (AATD) and WVE-007 (weight loss) as primary near-term value drivers. WVE-006 lags BEAM-302 in efficacy but offers a cleaner safety profile; pivotal 2026 data could narrow the efficacy gap and drive valuation upside. Wave’s $602M cash position supports operations into Q3 2028, with low immediate dilution risk and major catalysts pending for both lead programs. Valuation upside hinges on FDA validation of RNA editing, with risk-adjusted peak sales estimates supporting a potential $5.1B valuation versus a ~$1.4B market cap, with significant clinical trial binary risks. Read the full article on Seeking Alpha
Narrative Update • May 04
WVE: Obesity Data And 2026 Catalysts Will Shape Future Upside
Analysts have reduced their price targets on Wave Life Sciences, driving an internal fair value estimate from about $34.06 to $22.19 as they factor in updated revenue growth, margin expectations, and pipeline competitiveness against GLP-1 treatments. Analyst Commentary Recent research coverage on Wave Life Sciences has become more mixed, with a cluster of price target cuts around updated obesity data and GLP-1 competition, alongside a smaller group of firms that remain constructive on the pipeline and long term opportunity.
Narrative Update • Apr 19
WVE: Obesity And AATD Pipeline Progress Will Drive Future Upside
Analysts have reduced the average price target for Wave Life Sciences by about $1, reflecting a mix of lower Street targets after recent obesity and GLP-1 competitiveness concerns, partly offset by a few upward revisions following pipeline updates. Analyst Commentary Recent Street commentary around Wave Life Sciences has been mixed, with several firms cutting price targets and questioning the competitiveness of the obesity and GLP 1 pipeline, while a smaller group of bullish analysts has highlighted potential upside tied to clinical catalysts and management execution.Narrative Update • Apr 05
WVE: Obesity Pipeline Data And Regulatory Pathways Will Drive Future Upside
Analysts have adjusted the fair value estimate for Wave Life Sciences to $50.75 from $45.17, reflecting updated views on its obesity and AATD pipeline opportunities, as well as a mix of recent price target revisions across the Street. Analyst Commentary Recent research on Wave Life Sciences shows a split tape, with some firms turning more cautious while others highlight potential value in the obesity and AATD programs.Recent updates
Seeking Alpha • May 07
Wave Life Sciences: Good Platform, Mixed Clinical Trial Data, Hold
Summary Wave Life Sciences is advancing stereopure oligonucleotide therapeutics, with WVE-006 (AATD) and WVE-007 (weight loss) as primary near-term value drivers. WVE-006 lags BEAM-302 in efficacy but offers a cleaner safety profile; pivotal 2026 data could narrow the efficacy gap and drive valuation upside. Wave’s $602M cash position supports operations into Q3 2028, with low immediate dilution risk and major catalysts pending for both lead programs. Valuation upside hinges on FDA validation of RNA editing, with risk-adjusted peak sales estimates supporting a potential $5.1B valuation versus a ~$1.4B market cap, with significant clinical trial binary risks. Read the full article on Seeking AlphaNarrative Update • May 04
WVE: Obesity Data And 2026 Catalysts Will Shape Future Upside
Analysts have reduced their price targets on Wave Life Sciences, driving an internal fair value estimate from about $34.06 to $22.19 as they factor in updated revenue growth, margin expectations, and pipeline competitiveness against GLP-1 treatments. Analyst Commentary Recent research coverage on Wave Life Sciences has become more mixed, with a cluster of price target cuts around updated obesity data and GLP-1 competition, alongside a smaller group of firms that remain constructive on the pipeline and long term opportunity.Narrative Update • Apr 19
WVE: Obesity And AATD Pipeline Progress Will Drive Future Upside
Analysts have reduced the average price target for Wave Life Sciences by about $1, reflecting a mix of lower Street targets after recent obesity and GLP-1 competitiveness concerns, partly offset by a few upward revisions following pipeline updates. Analyst Commentary Recent Street commentary around Wave Life Sciences has been mixed, with several firms cutting price targets and questioning the competitiveness of the obesity and GLP 1 pipeline, while a smaller group of bullish analysts has highlighted potential upside tied to clinical catalysts and management execution.Narrative Update • Apr 05
WVE: Obesity Pipeline Data And Regulatory Pathways Will Drive Future Upside
Analysts have adjusted the fair value estimate for Wave Life Sciences to $50.75 from $45.17, reflecting updated views on its obesity and AATD pipeline opportunities, as well as a mix of recent price target revisions across the Street. Analyst Commentary Recent research on Wave Life Sciences shows a split tape, with some firms turning more cautious while others highlight potential value in the obesity and AATD programs.Narrative Update • Mar 22
WVE: Obesity Data And 2026 AATD Milestones Will Drive Future Upside
Analysts have nudged the fair value estimate for Wave Life Sciences to $34.06 from $33.50, reflecting updated views on its obesity and AATD pipeline progress and higher future P/E assumptions informed by recent price target revisions across the Street. Analyst Commentary Street research on Wave Life Sciences is centering on the obesity and AATD programs, with several firms updating their targets and models after recent management meetings and clinical readouts.Narrative Update • Mar 07
WVE: Obesity Fat Reduction Data Will Drive Future Upside Potential
Analysts have inched their fair value estimate for Wave Life Sciences higher from $33.38 to $33.50. This reflects updated views on WVE-007's obesity program and potential regulatory pathways, as well as the recent cluster of higher Street price targets that highlight upcoming data as a key near term catalyst.Narrative Update • Feb 20
WVE: INHBE Cardiometabolic Data And AATD Rights Will Drive Future Upside
Analysts have nudged their fair value estimate for Wave Life Sciences higher, with the updated target moving from about $33.06 to $33.38 as they factor in recent bullish coverage, higher Street price targets, and evolving views on revenue growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts have recently highlighted Wave Life Sciences as a name to watch, with several research shops updating their views and price targets in quick succession.Narrative Update • Feb 06
WVE: INHBE Fat Reduction And AATD Progress Will Drive Future Upside
Analysts increased their price target on Wave Life Sciences by about $1 to roughly $33 per share, as recent bullish coverage and supportive data for its INHBE-targeting approach and AATD program reinforced confidence in the company's long term potential. This was viewed as justification for a higher fair value estimate despite a slightly higher discount rate and modestly adjusted growth and margin assumptions.Narrative Update • Jan 22
WVE: Obesity And RNA Editing Progress Will Drive Future Upside Potential
Analysts have lifted their price targets on Wave Life Sciences, with our fair value estimate moving from US$32.60 to about US$45.17. This reflects growing confidence in its INHBE-targeting obesity program, validation of its RNA editing approach versus competitors, and supportive commentary around its Huntington’s disease and weight loss pipelines.Narrative Update • Jan 08
WVE: INHBE Obesity Program Will Drive Future Upside Potential
Analysts have inched up their fair value estimate for Wave Life Sciences to about $31.93 per share from $31.60. This reflects updated views on the company’s INHBE-targeting obesity program, strengthened competitive position in AATD, and continued interest in its broader genetic medicines pipeline.Narrative Update • Dec 24
WVE: Obesity RNA Editing Advances Are Expected To Drive Future Upside
Analysts have lifted their fair value estimate for Wave Life Sciences to approximately $31.60 per share from about $27.21, citing strengthened competitive positioning in genetic medicines, positive obesity pipeline data, and limited negative read-throughs from peer setbacks as key drivers. Analyst Commentary Bullish analysts highlight that recent competitive developments in alpha-1 antitrypsin deficiency have effectively de-risked Wave Life Sciences' editing approach, supporting higher confidence in long term market share and cash flow potential.Analysis Article • Dec 16
Subdued Growth No Barrier To Wave Life Sciences Ltd. (NASDAQ:WVE) With Shares Advancing 128%
The Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has done very well over the last month, posting an excellent...Narrative Update • Dec 10
WVE: Obesity RNA Editing Breakthrough Is Expected To Drive Future Upside
Analysts have raised their price target on Wave Life Sciences by about $7 per share, reflecting increased confidence in the companys validated RNA editing approach, its expanding obesity pipeline, and its insulated Huntington's disease program despite sector specific setbacks. Analyst Commentary Bullish analysts view recent sector developments as reinforcing Wave Life Sciences competitive positioning, particularly in RNA editing and obesity, and see room for further upside as the company executes on its clinical milestones.Analysis Article • Nov 01
Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have had a really impressive month, gaining 29% after a shaky period...Analysis Article • Sep 14
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have retraced a considerable 29% in the last month, reversing a fair...Analysis Article • Aug 04
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Trimmed Their Revenue Forecasts By 13%
One thing we could say about the analysts on Wave Life Sciences Ltd. ( NASDAQ:WVE ) - they aren't optimistic, having...Analysis Article • Jul 31
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 26% Share Price Surge Not Quite Adding Up
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders would be excited to see that the share price has had a great month...Analysis Article • Jul 07
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysis Article • Jun 01
Risks Still Elevated At These Prices As Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Dive 26%
Unfortunately for some shareholders, the Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has dived 26% in the last...Analysis Article • Apr 04
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 41% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Unfortunately for some shareholders, the Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has dived 41% in the last...Seeking Alpha • Mar 27
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
Summary Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved in the phase 2 FORWARD-53 study, using WVE-N531 for the treatment of patients with DMD amenable to exon 53 skipping; an average dystrophin expression of 7.8% was achieved. The Duchenne Muscular Dystrophy market, in the 7 major markets, will reach $5.2 billion by 2033. Positive FDA meeting held; potential for WVE to file for Accelerated Approval of WVE-N531 for DMD patients amenable to Exon 53 skipping in 2026. Read the full article on Seeking Alpha
New Narrative • Mar 23
WVE-007 And WVE-006 Will Offer New Treatment Options For Obesity And AATD
Advancing innovative treatments like WVE-007 and WVE-006 could drive revenue growth by addressing current therapy limitations and capturing market share in obesity and AATD.Seeking Alpha • Jan 08
Wave Life Sciences Is A Buy On Pipeline Prospects
Summary Wave Life Sciences develops stereopure oligonucleotides targeting genetic mutations, with lead assets in DMD, AATD, and Huntington's Disease showing promising data. Major collaborations with GSK and positive trial results have significantly boosted WVE's stock, despite previous flat performance and management missteps. Financially strong with $525M in cash, the Company has a solid runway for 8–10 quarters, though approval for its programs is still years away. Despite valuation risks, WVE's successful data, collaborations, and large target markets make it a buy; start small, accumulate at dips, and hold long term. Read the full article on Seeking AlphaAnalysis Article • Nov 15
US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results
Wave Life Sciences Ltd. ( NASDAQ:WVE ) missed earnings with its latest quarterly results, disappointing...Analysis Article • Nov 09
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking
Despite an already strong run, Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have been powering on, with a gain of 95...Seeking Alpha • Oct 16
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Summary Wave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration of 200 mg of WVE-006 resulted in the presence of wild-type alpha-1 antitrypsin protein; This led to a more than 60% increase of AAT. The global Alpha-1 Antitrypsin Deficiency market is expected to reach a $10 billion market value by 2033. Additional results from the phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of patients with alpha-1 Antitrypsin Deficiency, expected in 2025. Read the full article on Seeking AlphaAnalysis Article • Sep 25
There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump
Despite an already strong run, Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have been powering on, with a gain of 43...Seeking Alpha • Sep 24
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Summary Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531, showing >5% dystrophin production. The safety profile of WVE-N531 is strong, but competition from gene therapies and the need for further efficacy data present significant challenges. Investors should consider waiting for 48-week data and clearer regulatory paths before committing, despite WVE stock's current upside potential. Despite past setbacks, Wave's innovative RNA-targeting technology and strategic partnerships, like with GSK, position it for potential breakthroughs in multiple disease areas. A successfully approved DMD candidate could ultimately turn Wave into a double-digit billion company, like rival Sarepta Therapeutics, but that eventuality remains a long way off. Read the full article on Seeking AlphaAnalysis Article • Sep 08
Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher
Shareholders in Wave Life Sciences Ltd. ( NASDAQ:WVE ) may be thrilled to learn that the analysts have just delivered a...Analysis Article • Aug 05
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analysis Article • Jun 25
Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
You may think that with a price-to-sales (or "P/S") ratio of 5.7x Wave Life Sciences Ltd. ( NASDAQ:WVE ) is a stock to...Analysis Article • Apr 09
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 09
Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Summary Wave Life Sciences is entering the obesity market, selecting INHBE as a clinical candidate. The company faces intense competition from other RNA-based therapeutics companies, such as Alnylam, that have successfully brought treatments to market. Investment recommendation: Hold, due to intense competition, financial sustainability concerns, and current market sentiment. Read the full article on Seeking AlphaAnalysis Article • Mar 03
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders are no doubt pleased to see that the share price has bounced 30% in...Analysis Article • Sep 13
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analysis Article • May 08
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on Wave Life Sciences Ltd. ( NASDAQ:WVE ) - they aren't optimistic, having...Analysis Article • Mar 30
Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, Wave Life Sciences...Analysis Article • Jan 20
Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Key Insights Wave Life Sciences' estimated fair value is US$8.4 based on 2 Stage Free Cash Flow to Equity Current share...Shareholder Returns
| WVE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.5% | -1.9% | 2.1% |
| 1Y | 10.7% | 33.3% | 30.6% |
Return vs Industry: WVE underperformed the US Pharmaceuticals industry which returned 33.4% over the past year.
Return vs Market: WVE underperformed the US Market which returned 31% over the past year.
Price Volatility
| WVE volatility | |
|---|---|
| WVE Average Weekly Movement | 16.2% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: WVE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: WVE's weekly volatility has decreased from 24% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 317 | Paul B. Bolno | wavelifesciences.com |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD).
Wave Life Sciences Ltd. Fundamentals Summary
| WVE fundamental statistics | |
|---|---|
| Market cap | US$1.40b |
| Earnings (TTM) | -US$183.59m |
| Revenue (TTM) | US$71.80m |
19.4x
P/S Ratio-7.6x
P/E RatioIs WVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WVE income statement (TTM) | |
|---|---|
| Revenue | US$71.80m |
| Cost of Revenue | US$189.60m |
| Gross Profit | -US$117.80m |
| Other Expenses | US$65.79m |
| Earnings | -US$183.59m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | -164.07% |
| Net Profit Margin | -255.70% |
| Debt/Equity Ratio | 0% |
How did WVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 12:49 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wave Life Sciences Ltd. is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Whitney Ijem | Canaccord Genuity |